Article

Men may be at greater risk than women of developing HPV-related cancer

Author(s):

A new study from the National Cancer Institute suggests that the number of HPV-positive oral cancers among men could rise significantly in the next decade, possibly surpassing cervical cancers among women.The human papillomavirus is the most common sexually transmitted virus in the U.S., according to the Centers for Disease Control and Prevention. About 20 million Americans are currently infected and about 6 million more get infected each year.Using population-based cancer registry data, the researchers found that between 1988 and 2004, oropharynx cancers related to HPV increased by 225 percent, with men accounting for the majority of cases. Relying on U.S. Census projections and age-period-cohort models, they projected a 27 percent rise in cases by 2020.About 40 types of HPV are spread during genital, oral or anal sex with an infected partner--some are low-risk (wart-causing) while others are high-risk (cancer-causing). It is believed that the body's own immune system gets rid of most HPV within about two years of infection. But when HPV remains in the body for longer periods, it can develop into several cancers, including oropharynx and cervical, which is the second leading cause of cancer deaths in women worldwide.Gardasil, the only approved vaccine for boys and girls, is effective against two types of cancer-causing HPV and two types of wart-causing HPV.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Imiage of two doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Related Content